The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index; 4 of the 8 sources its claims cite were checked for support.
A prudent path forward for genomic engineering and germline gene modification
Open accessAbstract
A framework for open discourse on the use of CRISPR-Cas9 technology to manipulate the human genome is urgently needed , Genome engineering technology offers unparalleled potential for modifying human and nonhuman genomes. In humans, it holds the promise of curing genetic disease, while in other organisms it provides methods to reshape the biosphere for the benefit of the environment and human societies. However, with such enormous opportunities come unknown risks to human health and well-being. In January, a group of interested stakeholders met in Napa, California ( 1 ), to discuss the scientific, medical, legal, and ethical implications of these new prospects for genome biology. The goal was to initiate an informed discussion of the uses of genome engineering technology, and to identify those areas where action is essential to prepare for future developments. The meeting identified immediate steps to take toward ensuring that the application of genome engineering technology is performed safely and ethically.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
A 2015 Science policy forum from the Napa meeting argues that CRISPR-Cas9 genome engineering offers major promise but also unknown risks, especially for human germline modification. It recommends broad open discussion and, in the near term, strongly discouraging clinical human germline genome modification while research and governance proceed.
Key findings
- The Napa meeting concluded there is an urgent need for open discussion of the merits and risks of human genome modification by a broad cohort including scientists, clinicians, social scientists, the general public, and relevant public entities and interest groups.
- Near-term recommendations include strongly discouraging germline genome modification for clinical application in humans, even in lax jurisdictions; creating expert forums for education; encouraging transparent research on efficacy and specificity in human and nonhuman model systems; and convening a globally representative group to consider policies.
- The paper notes that human germline engineering methods have already been demonstrated in mice and monkeys, and it distinguishes mitochondrial transfer—which does not use CRISPR-Cas9 and was approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom—from nuclear germline editing.
- No quantitative data or effect sizes are reported; the text is a consensus policy commentary.
Methods
- Design: policy forum/commentary reporting on a January 2015 Napa, California meeting of CRISPR-Cas9 developers and users and experts in genetics, law, and bioethics; all participants were from the United States.
- Data or sample: no empirical dataset; discussion focused on human germline engineering and did not address mitochondrial transfer.
- Main analysis: consensus discussion and recommendations for governance, risk assessment, public engagement, and research priorities.
Limitations
- Stated: the Napa discussion did not address mitochondrial transfer; the group was all from the United States, and the paper calls for globally representative participation.
- Stated: limits to knowledge of human genetics, gene-environment interactions, and disease pathways create uncertainty about unintended consequences of heritable germline modifications.
- Evident from the text: the recommendations are not based on systematic data or quantitative risk assessment and are advisory rather than binding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 8 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“focused on the issue of human germline engineering, as the methods have already been demonstrated in mice (6) and monkeys (7).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Supportedcites [6] Wang H Cell 2013 153 910 Medline 23643243 PMC3969854 source
The Introduction states that the authors use CRISPR/Cas to edit multiple genes in stem cells and mice, and the Discussion reports generating mice with multiple genetic alterations. This source supports the mice portion of the citing sentence; the monkeys portion is assigned to a separate citation. (LLM, conf=0.93)
- Supportedcites [7] Niu Y Cell 2014 156 836 Medline 24486104 source
The citation to this paper supports the monkey part of the sentence. The Summary reports CRISPR/Cas9 gene targeting in one-cell-stage cynomolgus monkey embryos and the generation of gene-modified monkeys; the mice citation is separate. (LLM, conf=0.93)
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The technique also allows DNA sequence changes in pluripotent embryonic stem cells (4) that can then be cultured to produce specific tissues, such as cardiomyocytes or neurons (5).”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
What the sources say
- Partly supportedcites [4] Mali P Science 2013 339 823 Medline 23287722 PMC3712628 sourceExperimental — accuracy not yet measured
The paper’s genome-targeting results report CRISPR-Cas9 editing in human induced pluripotent stem (iPS) cells, supporting the claim that the technique can change DNA in pluripotent cells. It does not report editing embryonic stem cells; the citing sentence attaches this source to that part, while assigning the tissue-differentiation claim to citation (5). (LLM, conf=0.88)
- Supportedcites [5] Zhu Z González F Huangfu D Methods Enzymol 2014 546 215 Medline 25398343 PMC4418970 source
Citation (4) is attached to the claim that CRISPR-Cas9 allows DNA sequence changes in pluripotent embryonic stem cells, not to the later examples of cardiomyocytes or neurons. The Introduction identifies human embryonic stem cells as human pluripotent stem cells and describes CRISPR/Cas genome editing in those cells; Section 2 reports highly efficient editing at target loci. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
In the paper
“Although characterized by some as another form of “germline” engineering, mitochondrial transfer raises different issues and has already been approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine and the Food and Drug Administration in the United States (11).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Not matchedcites [11] U.S. Food and Drug Administration, Cellular, Tissue, and Gene Therapies Advisory Committee Meeting: Announcement www.fda.gov/AdvisoryCommittees/Calendar/ucm380042.htm; www.iom.edu/activities/research/mitoethics.aspx.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Humans are no exception—changes to the human germ line could be made using this simple and widely available technology.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
In the paper
“For example, the CRISPR-Cas9 system enables introduction of DNA sequence changes that correct genetic defects in whole animals, such as replacing a mutated gene underlying liver-based metabolic disease in a mouse model (3).”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
What the sources say
- Not checked yetcites [3] Yin H Nat. Biotechnol 2014 32 551 Medline 24681508 PMC4157757 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Even this seemingly straightforward scenario raises serious concerns, including the potential for unintended consequences of heritable germline modifications,”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: There are limits to current knowledge of human genetics, gene-environment interactions, and disease pathways.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 3
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Such studies are laying the groundwork for refined approaches that could eventually treat human disease.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
In the paper
“Although characterized by some as another form of “germline” engineering, mitochondrial transfer raises different issues and has already been approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine and the Food and Drug Administration in the United States (11).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Not checked yetcites [10] The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 www.legislation.gov.uk/uksi/2015/572/contents/made (effective 29 October 2015).
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“However, this limitation has been upended by the rapid development and widespread adoption of a simple, inexpensive, and remarkably effective genome engineering method known as clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 (2).”
§ A prudent path forward for genomic engineering and germline gene modification > Abstract
What the sources say
- Not matchedcites [2] Doudna JA Charpentier E Science 2014 346 1258096 Medline 25430774
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The simplicity of the CRISPR-Cas9 system allows any researcher with knowledge of molecular biology to modify genomes, making feasible experiments that were previously difficult or impossible to conduct.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, it is now possible to carry out genome modification in fertilized animal eggs or embryos, thereby altering the genetic makeup of every differentiated cell in an organism and so ensuring that the changes will be passed on to the organism’s progeny.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
- Rests on an assumption: CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
The paper relies on this without support.
There are limits to current knowledge of human genetics, gene-environment interactions, and disease pathways.
“because there are limits to our knowledge of human genetics, gene-environment interactions, and the pathways of disease (including the interplay between one disease and other conditions or diseases in the same patient).”
The paper relies on this without support.
In the United States, human research involving heritable germline modifications currently would require an Investigational New Drug exemption from the FDA.
“In the United States, such human research currently would require an Investigational New Drug exemption from the Food and Drug Administration”
The paper relies on this without support.
In countries with a highly developed bioscience capacity, germline genome modification in humans is currently illegal or tightly regulated.
“(In countries with a highly developed bioscience capacity, germline genome modification in humans is currently illegal or tightly regulated.)”
The paper relies on this without support.
Mitochondrial transfer does not use CRISPR-Cas9.
“The Napa discussion did not address mitochondrial transfer (8, 9), a technique that does not use CRISPR-Cas9.”
The paper relies on this without support.
Public trust in science ultimately begins with and requires ongoing transparency and open discussion.
“At the dawn of the recombinant DNA era, the most important lesson learned was that public trust in science ultimately begins with and requires ongoing transparency and open discussion.”
The paper relies on this without support.
CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
“In addition to facilitating changes in differentiated somatic cells of animals and plants, CRISPR-Cas9 technology as well as other genome engineering methods can be used to change the DNA in the nuclei of reproductive cells that transmit information from one generation to the next (an organism’s “germ line”).”
The paper relies on this without support.
Off-target alterations and on-target events with unintended consequences are possible with CRISPR-Cas9.
“Considerations include the possibility of off-target alterations, as well as on-target events that have unintended consequences.”
The authors state this as an assumption.
The safety and efficacy of genome engineering technology can be ensured.
“Assuming the safety and efficacy of the technology can be ensured, a key point of discussion is whether the treatment or cure of severe diseases in humans would be a responsible use of genome engineering, and if so, under what circumstances.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subsequent report of the results of the conference was published in March 2015 in the journal Science [46], which essentially carried recommendations to strongly discourage work on introducing heritable changes in human embryonic cells, at least for the duration of active discussions of the social, environmental and ethical consequences of such manipulations.”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [46]
Citations
Cites
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Self-citationWang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Niu, Y., Shen, B., Cui, Y., Chen, Y., Wang, J., Wang, L., Kang, Y., Zhao, X., Si, W., Li, W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.027 · Cited by 1,033
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Towards germline gene therapy of inherited mitochondrial diseases
Tachibana, M., Amato, P., Sparman, M. L., Woodward, J., Melguizo‐Sanchis, D., Ma, H., Gutiérrez, N. M., Tippner-Hedges, R., Kang, E., Lee, H.-S., et al. (2012) · Nature · doi:10.1038/nature11647 · Cited by 429
The iCRISPR Platform for Rapid Genome Editing in Human Pluripotent Stem Cells
Zhu, Z., González, F., & Huangfu, D. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801185-0.00011-8 · Cited by 66
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 733
Applications of innovative gene-editing technologies in respiratory diseases
El-Hashash, A. H. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821206-6.00004-7
General discussion, conclusion remark, and future direction
El-Hashash, A. H. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821206-6.00001-1
Towards a Global Germline Ethics?
Chan, S. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108620024.043
On the Ethical Issues of Gene-enhancement in Different Stages of Human Development
Jiang, J. (2021) · Advances in Sciences and Humanities · doi:10.11648/j.ash.20210702.12
A review of progress in the CRISPR/Cas9
Lu, K., & Fu, X. (2020) · International Symposium on the Frontiers of Biotechnology and Bioengineering (FBB) · doi:10.23977/fbb2020.027
The freedom of scientific research
(2020) · Manchester University Press eBooks · doi:10.7765/9781526146472
Resnik, D. B. (2021) · The International Library of Bioethics · doi:10.1007/978-3-030-70791-0_7
Ginn, S. L., & Alexander, I. E. (2016) · Wiley eBooks · doi:10.1002/9781118445112.stat06926.pub2
Cossart, P. (2018) · ASM Press eBooks · doi:10.1128/9781683670117.biblio
Gene Editing Through CRISPR-Based Technology
Zhang, Z., Wang, P., & Liu, J. (2022) · Springer eBooks · doi:10.1007/978-981-16-8504-0_2
Development and Vision of CRISPR-Based Technology
Zhang, Z., Wang, P., & Liu, J. (2022) · Springer eBooks · doi:10.1007/978-981-16-8504-0_1
Islamic Sunni perspectives on the ethics of precision medicine
Suleman, M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0017
Personalized medicine and disorders of consciousness
Fins, J. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0010
The revolution of personalized medicine is already upon us in rare diseases
Austin, C. P. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0009
Gender and personalized medicine
Legato, M. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0011
Personalized medicine and genetic newborn screening
Brusa, M., & Dickenson, D. L. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0008
Genetics, genetic profiles, and Jewish law
Weissinger, Y., & Barilan, Y. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0018
Precision and persons in medicine
Barilan, Y. M., & Brusa, M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0001
Evans, J. H. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780197519561.003.0001
(2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803693-8.16001-3
Srihari, S., Yong, C. H., & Wong, L. (2017) · doi:10.1145/3064650.3064660
CRISPR‐Cas: Ein universelles Werkzeug für die Gentechnik
(2016) · Nachrichten aus der Chemie · doi:10.1002/nadc.20164047295
de Melo‐Martín, I. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780190460204.003.0002
Case Study: H5N1 Influenza Research Debate
Rozell, D. J. (2020) · Ubiquity Press eBooks · doi:10.5334/bci.a
Assessing the Benefits of Research
Rozell, D. J. (2020) · Ubiquity Press eBooks · doi:10.5334/bci.b
Srihari, S., Yong, C. H., & Wong, L. (2017) · doi:10.1145/3064650.3064661
Evans, J. H. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780197519561.003.0005
(2013) · Biology & Philosophy · doi:10.1007/10539.1572-8404
Srihari, S., Yong, C. H., & Wong, L. (2017) · doi:10.1145/3064650.3064651
Minor, L. B., & Rees, M. J. (2020) · Wiley eBooks · doi:10.1002/9781119672715.notes
Rozell, D. J. (2020) · Ubiquity Press eBooks · doi:10.5334/bci.e
Ehmoser, E.-K., & Tan, D. (2018) · Learning materials in biosciences · doi:10.1007/978-3-319-73123-0_5
Alkuraya, F. S. (2022) · Clinical Genetics · doi:10.1111/cge.14209
Simonstein, F. (2022) · The International Library of Bioethics · doi:10.1007/978-3-031-11654-4_8
Future Technological Advancements
Doxzen, K. W. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197616192.003.0011
Habib, É., & Larouche, P. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.3498384
Belachew, G. T. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.48.007711
Graumann, S. (2023) · J.B. Metzler eBooks · doi:10.1007/978-3-476-05869-0_102
(2022) · Actual problems of modern medicine · doi:10.26565/2617-409x-2022-9
Gene Editing Technology Patents or Monopolization of Scientific Knowledge and Health Care?
Machnicka, A. A. (2023) · MPI studies on intellectual property and competition law · doi:10.1007/978-3-662-65974-8_24
Crispr-a novel approach towards a fortified immune system
Ranganathan, V., Madham, P., Shankpal, P., & Sheri, C. (2023) · Journal of Microbiology & Experimentation · doi:10.15406/jmen.2023.11.00391
Transhumanismo: ¿homo sapies o ciborg? I Ponencias
de Vitoria, U. F., & Lacalle, M. (2022) · Editorial UFV eBooks · doi:10.32466/eufv-11
Genetic Enhancement of the Human Being - Between Reality and Fiction, Between Risks and Benefits
Hanganu, B., Manoilescu, I. S., & Ioan, B. G. (2023) · Journal of Intercultural Management and Ethics · doi:10.35478/jime.2023.3.06
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 for Therapeutic Gene Correction
Walther, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2032
Ushakiran, G., Pradeepa, S. G. S., Lavanya, S., Priya, T. S., & Kumari, P. K. (2023) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2023.20.3.2057
Zum ethischen Paradigmenwechsel in der Debatte um (erbliches) Genome-Editing an Embryonen in vitro
Schickl, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_18
Políticas judiciárias das demandas de saúde e o respeito à bioética
Kim, R. P. (2023) · Direito da Saúde Comparado · doi:10.56242/direitodasaudecomparado;2023;2;2;137-157
Barilan, Y. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.002.0005
Barilan, Y. M., Brusa, M., & Ciechanover, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.002.0006
Barilan, Y. M., Brusa, M., & Ciechanover, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.002.0003
Evans, J. H. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780197519561.002.0003
Evans, J. H. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780197519561.002.0007
Transmission regulating immune genes: A potential strategy to control vector-borne disease
Srivastava, H., Gupta, B., Ali, M. I., & Moin, S. (2024) · Journal of Vector Borne Diseases · doi:10.4103/jvbd.jvbd_157_23
Genome engineering and bioethics
Khurshid, K., Amir, R., Gul, A., Maqsood, W., Junaid, M., Sabih, F. M., & Javed, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26614-0.00021-7
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0005
From the Universal Declaration to the Covenant on Economic, Social, and Cultural Rights
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0003
The Right to Science in National Constitutions
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0007
UNESCO and the Right to Science
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0005
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0012
The United Nations and the Right to Science
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0004
Table of Constitutions and Constitutional Legal Instruments
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0014
The Future of the Right to Science
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0013
From the American Declaration to the Universal Declaration of Human Rights
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0002
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0001
The Right to Responsible Scientific Progress (Scientific Responsibility)
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0010
Table of International Legal Instruments and Other International Organizations’ Documents
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0013
Finding the Normative Content of the Right to ScienceAn Introduction
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0008
The Right to Benefit from Scientific Progress
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0012
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0008
The Right to Participate in Scientific Progress
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0011
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0007
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0010
The Right to Scientific Progress and to Scientific Freedom
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0009
Regional Human Rights Regimes and the Right to Science
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.003.0006
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0011
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0004
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.002.0003
Editing Life: Homo sapiens as Evolutionary Drive
Pievani, T. (2024) · Springer eBooks · doi:10.1007/978-3-031-61187-2_6
Bilimin Serüveni Bilim Felsefesi
Özen, Y., Avşaroğlu, S., & Pilten, P. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3374
Оценка рисков генетической технологии CRISPR/Cas9
ПЕСТРИКОВА, А. А., & Kholopova, E. N. (2020) · Современное право. · doi:10.25799/ni.2020.68.12.014
Cнятие моратория на редактирование зародышевой линии человека: проблемы правового регулирования
ПЕСТРИКОВА, А. А. (2021) · Современное право. · doi:10.25799/ni.2021.89.54.018
CRISPR/Cas9 gene editing for treating gene and protein disorders
Umeyor, C. E., Negi, P., Agarwal, R., Hanjankar, S. N., & Patravale, V. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00004-6
CRISPR/Cas9-Based Genome Editing in Precision Medicine: Current Trends and Recent Advancements
Ullah, I. (2024) · Premier Journal of Genetics · doi:10.70389/pjg.100001
Genome Editing Technologies: Historical Roots, Current Landscape, and Future Directions
Alatiyyah, F. M., Tombuloğlu, H., Alhamid, G., Alhamid, A., Zidan, R., Turumtay, H., Karagöz, A., & Rabaan, A. A. (2025) · Genetics. · doi:10.5772/intechopen.1011421
Gene Therapy & Gene-Editing Techniques
LaRocca, C. J., & Steer, C. J. (2025) · Success in academic surgery · doi:10.1007/978-3-031-83034-1_13
Brown, J. (2024) · The Conversation · doi:10.64628/ade.xtxd6aadm
Bioengineers today emphasize the crucial ingredient Dr. Frankenstein forgot – responsibility
Haydon, I. C. (2018) · The Conversation · doi:10.64628/aai.jr93arra3
Bessen, J. L. (2015) · The Conversation · doi:10.64628/aai.rsawvswcf
Application of genetic scissoring in the management of genetically related diseases
Ogunlakin, A. D., Olusegun, O. V., Olusegun, S., Anejukwo, D. S., Asaleye, O., Balogun, H., Adedoyin, O. G., Ojo, O. A., Ogunlakin, O. A., & Sonibare, M. A. (2025) · Dietary Supplements and Nutraceuticals · doi:10.31989/dsn.v4i8.1730
Thompson, P. B. (2025) · The international library of environmental, agricultural and food ethics/The International library of environmental, agricultural and food ethics · doi:10.1007/978-3-032-04450-1_8
Creating a path to meaningful public participation: the case of heritable human genome editing
Güttinger, S. (2025) · Zeitschrift für Ethik und Moralphilosophie · doi:10.1007/s42048-025-00232-6
Sandhu, A. S., Anas, M., Eisha, Shoukat, S., Talha, M., Chorahi, M. U., Arif, M. I., & Arbab, Q. U. A. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i6.1754
Remembering David Baltimore (1938–2025)
Daley, G. Q. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.023
Self-citationMolecular mastery: Harnessing DNA technology for disease prevention
Dornadula, G., Ramakrishna, C., Shaik, S. B., Meriga, P. K., Chintha, L., Gurugari, Y., D., K., Shaik, S. F., & Cheong, S. H. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101976
Additional file 1 of Researching the future: scenarios to explore the future of human genome editing
Selin, C. L., Lambert, L. M., Morain, S. R., Nelson, J. P., Barlevy, D., Farooque, M., Manley, H., & Scott, C. T. (2023) · Figshare · doi:10.6084/m9.figshare.24180822
Keimbahntherapie durch CRISPR/Cas9
Hummel, N. R. (2020) · Digital Library of the University of Innsbruck (University of Innsbruck)
Vierter Gentechnologiebericht : Bilanzierung einer Hochtechnologie (Edition 1)
(2018) · BiblioBoard Library Catalog (Open Research Library)
Advanced Technologies in Nutrigenomics Research
Prof. Tamilchudar, R., Arivuchudar, R., & Sendilkumar, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-12415-9_5
Metadata
- Authors
- Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., Greely, H. T., Jinek, M., Martin, G. S., Penhoet, E., Puck, J., Sternberg, S. H., Weissman, J. S., & Yamamoto, K. R.
- Affiliations
- California Institute of Technology (US)
- Stanford Medicine (US)
- Innovative Genomics Institute (US)
- University of Utah (US)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Boston Children's Hospital (US)
- Howard Hughes Medical Institute (US)
- Stanford University (US)
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
- University of California, Berkeley (US)
- Alta Partners, One Embarcadero Center, 37th Floor, San Francisco, CA 94111, USA.
- University of California, San Francisco (US)
- Corresponding author
- Doudna, Jennifer A.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 36-38
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4394183
- OpenAlex
- W1987739153
- Cited by
- 733
- References
- 7
- Citations by year
- 2026: 37 · 2025: 28 · 2024: 48 · 2023: 34 · 2022: 52 · 2021: 46 · 2020: 77 · 2019: 74 · 2018: 75 · 2017: 96 · 2016: 80 · 2015: 84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Caribou Biosciences, Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
- Keywords
- CRISPR/Cas9, germline editing, public discourse, genome editing regulation
- MeSH terms
- Biotechnology, Genetic Engineering, Germ Cells, Humans, Risk Management, Genome, Human, Genetic Predisposition to Disease, Gene Transfer, Horizontal, Genomics, Targeted Gene Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
